|
|
Volumn , Issue , 2009, Pages 555-565
|
|
How to treat a newly diagnosed young patient with multiple myeloma.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BORONIC ACID DERIVATIVE;
BORTEZOMIB;
DOXORUBICIN;
DRUG DERIVATIVE;
ETOPOSIDE;
LENALIDOMIDE;
MYELOABLATIVE AGENT;
PYRAZINE DERIVATIVE;
THALIDOMIDE;
VAD COMBINATION;
ADULT;
AGE;
BIOASSAY;
CHROMOSOME ABERRATION;
DIAGNOSTIC PROCEDURE;
DISEASE MANAGEMENT;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
METHODOLOGY;
MIDDLE AGED;
MULTICENTER STUDY;
MULTIMODALITY CANCER THERAPY;
MULTIPLE MYELOMA;
RANDOMIZED CONTROLLED TRIAL;
REMISSION;
REVIEW;
ADULT;
AGE FACTORS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BORONIC ACIDS;
CHROMOSOME ABERRATIONS;
COMBINED MODALITY THERAPY;
DISEASE MANAGEMENT;
DOXORUBICIN;
ENDPOINT DETERMINATION;
ETOPOSIDE;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMANS;
MIDDLE AGED;
MOLECULAR DIAGNOSTIC TECHNIQUES;
MULTICENTER STUDIES AS TOPIC;
MULTIPLE MYELOMA;
MYELOABLATIVE AGONISTS;
PYRAZINES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
REMISSION INDUCTION;
THALIDOMIDE;
TRANSPLANTATION CONDITIONING;
|
|
EID: 77949453451
PISSN: None
EISSN: 15204383
Source Type: Journal
DOI: 10.1182/asheducation-2009.1.555 Document Type: Review |
|
Times cited : (23)
|
|
References (42)
|
